SCHEMBL5567705

SCHEMBL5567705

CCCCCc1cc(Cl)nnc1Cl

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.38
ALOX5 P09917 5/20 0.37
CYP3A4 P08684 2/20 0.37
TYR P14679 2/20 0.37
MEN1 O00255 1/20 0.37
TP53 P04637 1/20 0.37
MAPT P10636 1/20 0.37
ALOX15 P16050 1/20 0.37
TSHR P16473 1/20 0.37
HTT P42858 1/20 0.37
KMT2A Q03164 1/20 0.37
TLR8 Q9NR97 1/20 0.36
PTGS2 P35354 6/20 0.34
LIPG Q9Y5X9 1/20 0.34
KCNH2 Q12809 1/20 0.33
GABRA2 P47869 2/20 0.33
GABRB2 P47870 2/20 0.33
CTRC Q99895 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7832727 0.98 ALOX5 (0.40) TDP1ALOX5CYP3A4TYRMEN1
SCHEMBL1268563 0.94 TDP1 (0.39) TDP1ALOX5CYP3A4TYRMEN1
SCHEMBL7832945 0.86 TDP1 (0.41) TDP1
SCHEMBL30951372 0.82 TDP1 (0.39) TDP1
SCHEMBL2877727 0.81 TLR8 (0.47) TLR8
SCHEMBL7829368 0.80 TLR8 (0.40) TDP1ALOX5CYP3A4TYRMEN1
SCHEMBL27325471 0.80 TDP1 (0.40) TDP1
SCHEMBL23748091 0.78 TDP1 (0.39) TDP1TLR8
SCHEMBL31426179 0.78 TDP1 (0.43) TDP1
SCHEMBL30951365 0.78 TDP1 (0.39) TDP1TLR8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180346470-A1 CHEMICAL COMPOUNDS PFIZER LIMITED (GB) 2018-12-06 US disclosed
EP-3386983-A1 4-(BIPHEN-3-YL)-1H-PYRAZOLO[3,4-C]PYRIDAZINE DERIVATIVES OF FORMULA (I) AS GABA RECEPTOR MODULATORS FOR USE IN THE TREATMENT OF EPILEPSY AND PAIN Pfizer Limited (GB) 2018-10-17 EP disclosed
WO-2017098367-A1 4-(BIPHEN-3-YL)-1H-PYRAZOLO[3,4-C]PYRIDAZINE DERIVATIVES OF FORMULA (I) AS GABA RECEPTOR MODULATORS FOR USE IN THE TREATMENT OF EPILEPSY AND PAIN PFIZER LIMITED (GB) 2017-06-15 WO disclosed
US-7300932-B2 Pyrrolo[1,2-b]pyridazine derivatives JAPAN TOBACCO INC. (JP) 2007-11-27 US disclosed
EP-1653969-A4 PYRROLO 1,2-B PYRIDAZINE DERIVATIVES JAPAN TOBACCO INC (JP) 2006-12-20 EP disclosed
EP-1653969-A2 PYRROLO 1,2-B PYRIDAZINE DERIVATIVES Japan Tabacco Inc. (JP) 2006-05-10 EP disclosed
US-20050070545-A1 For treatment or prevention of metabolic and cell proliferative diseases; modifying lipid metabolism TULARIK INC. (US) 2005-03-31 US disclosed
WO-2005013907-A2 PYRROLO[1,2-B]PYRIDAZINE DERIVATIVES JAPAN TOBACCO INC. (JP) 2005-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050070545-A1 For treatment or prevention of metabolic and cell proliferative diseases; modifying lipid metabolism PC, ACACB, ACAT1 TDP1 3788/4885ALOX5 385/4885CYP3A4 3957/4885
US-20180346470-A1 CHEMICAL COMPOUNDS P2RX5, GABRA5, P2RX3 TDP1 1934/4885ALOX5 852/4885CYP3A4 83/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.